Associated tags: RSV, Infection, HPV, Norovirus, Respiratory syncytial virus, Cancer, Vaccination, SAN, Vaxart, Pharmaceutical industry, Vaccine, Webcast, Conference
Locations: NEW YORK, WASHINGTON, SPAIN, WALL STREET, SAN FRANCISCO, CA, US, BARDA, JAPAN, UNITED STATES
Retrieved on:
Wednesday, March 27, 2024
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024.
Key Points:
- SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World Vaccine Congress Washington 2024 in Washington, D.C. on Wednesday, April 3, 2024.
- The Company has appeared repeatedly at the annual event in Washington, D.C.
Retrieved on:
Wednesday, March 20, 2024
The awards were made pursuant to the Company’s previously disclosed offer letter with Mr.
Key Points:
- The awards were made pursuant to the Company’s previously disclosed offer letter with Mr.
- Lo, and as a material inducement to his joining the Company as President and Chief Executive Officer and a member of the Board of Directors.
- The awards were granted under the Vaxart, Inc. 2024 Inducement Award Plan as an employment “inducement award” pursuant to Nasdaq Listing Rule 5635(c)(4).
- The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Vaxart (or following a bona fide period of non-employment) as an inducement material to entering into employment with Vaxart.
Mother,
Research,
Breast milk,
Conference call,
Development,
Bill,
Webcast,
COVID-19,
SAN,
VOC,
GI,
Messenger,
XBB,
NHP,
SARS-CoV-2,
Insurance,
Investment,
Clinical trial,
Antibody,
Safety,
Vaxart,
Nextgen,
Vaccine,
FDA,
Food,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
Key Points:
- ET
SOUTH SAN FRANCISCO, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced its business update and financial results for the full year 2023.
- Financial Results for the Full Year Ended December 31, 2023
Cash, cash equivalents and investments totaled $39.7 million as of December 31, 2023.
- Vaxart reported a net loss of $82.5 million for the full year 2023, compared to $107.8 million for the full year 2022.
- The Vaxart senior management team will host a conference call to discuss the business update and financial results for the full year 2023 today, beginning at 4:30 p.m.
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.
Key Points:
- SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended December 31, 2023 after the market close on Thursday, March 14, 2024.
- The Vaxart senior management team will host a conference call on the same day, beginning at 4:30 p.m.
- ET.
- The conference call can be accessed using the following information:
A replay of the webcast will be available on the Company’s website at www.vaxart.com following the conclusion of the event.
Therapy,
SAN,
AstraZeneca,
Biotechnology,
University,
Puma Biotechnology,
Drug development,
Endocrinology,
Genentech,
Roche,
Kaiser Permanente,
Management SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that it has appointed Steven Lo as President and Chief Executive Officer and a member of the Board of Directors, effective as of March 18, 2024. Mr. Lo is a highly experienced biopharma executive with over 25 years of experience in the healthcare, biotechnology, and pharmaceutical industries, including over 12 years of C-level experience in publicly traded biotech companies. Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.
Key Points:
- Michael J. Finney, Ph.D. will step down as interim Chief Executive Officer and will continue to serve as Chair of the Board of Directors.
- Lo.
- Lo was most recently with Valitor, Inc., a private biotech company, serving as its Chief Executive Officer and a member of the board of directors since 2022.
- Lo was the President, Chief Executive Officer, and member of the board of directors of Zosano Pharma Corporation, a clinical-stage biopharmaceutical company.
SARS-CoV-2,
COVID-19,
SAN,
Norovirus,
Volatile organic compound,
Vaxart,
Animal,
Disease,
Immunoglobulin G,
Vaccination,
Infection,
Immunoglobulin A,
VOC,
Serum,
Development,
Immunization,
Vaccine SOUTH SAN FRANCISCO, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced the publication of preclinical non-human primate data demonstrating the potential of its COVID-19 vaccine to protect against multiple SARS-CoV-2 variants of concern (VOC)s. The data, which were previously presented at the International Congress of Mucosal Immunology 2022, are reported in the current issue of Vaccines.
Key Points:
- “The data published in Vaccines support the potential of our vaccine platform to stimulate potent mucosal cross-reactive IgA responses to multiple VOCs and reduce viral transmission.
- All three vaccines induced neutralizing antibodies in both the peripheral and mucosal compartments, which was enhanced with a boost immunization.
- Viral replication and infectious particle shedding were significantly reduced in immunized animals after challenge with beta variant SARS-CoV-2.
- Vaxart believes these data support the potential for its vaccines to enhance mucosal responses and reduce community transmission, in addition to preventing severe disease.
Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
Key Points:
- Each stock is evaluated based on short-term technical, long-term technical and fundamental factors.
- Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
- InvestorsObserver provides patented technology to some of the biggest names on Wall Street and creates world-class investing tools for the self-directed investor on Main Street.
- We have a wide range of tools to help investors make smarter decisions when investing in stocks or options.
Development,
Nextgen,
Research,
SAN,
COVID,
Administration,
Vaxart,
Vaccination,
Infection,
Pandemic,
COVID-19,
HHS,
Therapy,
Human services,
Messenger,
Vaccine,
XBB,
SARS-CoV-2,
Pharmaceutical industry SOUTH SAN FRANCISCO, Calif., Jan. 19, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that the United States Biomedical Advanced Research and Development Authority (BARDA) has awarded the Company $9.27 million to fund preparation for a 10,000 subject Phase 2b clinical study evaluating Vaxart’s oral pill XBB COVID-19 vaccine candidate against an approved mRNA vaccine comparator.
Key Points:
- “We are very honored to receive this BARDA award, which will support the innovative approach of our oral pill vaccine platform,” said Dr. Michael Finney, Vaxart’s Interim Chief Executive Officer.
- “We believe our oral pill vaccine platform may ultimately hold the promise of revolutionizing how we fight pandemics and how we vaccinate against several infectious diseases.
- Second, our previous research on other vaccine constructs found Vaxart’s oral pill vaccine to be cross-reactive against all tested SARS-CoV-2 variants and to trigger long-lasting immune responses, potentially offering broader, longer protection than the current first-generation vaccines.
- Vaxart’s oral pill vaccine platform provides many of the features desired by BARDA, such as generating mucosal immunity and providing a cross-reactive response to many COVID variants.
Retrieved on:
Tuesday, January 16, 2024
SAN,
Vaxart,
Prospectus,
Public expenditure,
Form,
Public,
Sale,
Suite,
Form S-3,
Telephone,
Security (finance) SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that it has entered into a common stock purchase agreement with RA Capital Management for the sale of 15,384,615 shares of its common stock in a registered direct offering at an offering price of $0.65 per share.
- Gross proceeds are approximately $10.0 million, before deducting expenses payable by Vaxart.
- Vaxart intends to use the net proceeds from the offering primarily for general corporate purposes, including working capital, operating expenses and capital expenditures.
- “We appreciate the financial backing by RA Capital as we continue to progress our oral pill vaccine platform,” said Dr. Michael J. Finney, Vaxart’s Interim Chief Executive Officer.
Retrieved on:
Tuesday, January 16, 2024
SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in management. Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Vaxart as President, Chief Executive Officer, and Director on Vaxart’s Board of Directors. Michael J. Finney, Ph.D., the Chair of Vaxart’s Board of Directors, has assumed the role of Interim Chief Executive Officer to lead the management team through this transition. Vaxart is conducting a CEO search for Mr. Floroiu’s successor.
Key Points:
- SOUTH SAN FRANCISCO, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced a change in management.
- Effective immediately Andrei Floroiu, President and Chief Executive Officer of Vaxart, has announced his resignation from his positions with Vaxart as President, Chief Executive Officer, and Director on Vaxart’s Board of Directors.
- Michael J. Finney, Ph.D., the Chair of Vaxart’s Board of Directors, has assumed the role of Interim Chief Executive Officer to lead the management team through this transition.
- He will continue on the Board of Directors while serving as Interim Chief Executive Officer.
